SABEY
1
11M
1
0.02
- Areas of investment
Summary
SABEY appeared to be the Corporate Investor, which was created in 1971. The main office of represented Corporate Investor is situated in the Seattle. The venture was found in North America in United States.
The important activity for fund was in 2017. The fund is generally included in less than 2 deals every year. The common things for fund are deals in the range of 10 - 50 millions dollars.
Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Health Diagnostics, Health Care. Among the most popular portfolio startups of the fund, we may highlight Indi Molecular. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
The typical case for the fund is to invest in rounds with 4 participants. Despite the SABEY, startups are often financed by InterWest Partners, Asset Management Ventures (AMV). The meaningful sponsors for the fund in investment in the same round are M Ventures, Legend Capital, Asset Management Ventures (AMV).
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Rounds per year
- 0.02
- Investments by industry
- Health Care (1)
- Health Diagnostics (1)
- Biotechnology (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2017
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Indi Molecular | 29 Jun 2017 | Biotechnology, Health Care, Health Diagnostics | Early Stage Venture | 11M | United States, California |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.